3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Breast Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
30 days
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled
NCT06445972
2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
210 enrolled